BD unveils plan for €165 million Spanish manufacturing plant
pharmafile | May 19, 2021 | News story | Research and Development | EU, manufacturing
BD has announced plans to build a new €160 million manufacturing plant in Zaragoza, located in the Aragon region of Spain, which will produce drug delivery devices and employ up to 600 people.
Construction of the new plant, the fourth facility for BD in Spain, is set to begin late this year. The site will initially have a workforce of 150 people and encompass an area of 8,000m2, with an expectation of expansion to 600 people and an area of 30,000m2 by 2030.
The site will be fully digital, incorporating utonomous technologies, also knowns as Industry 4.0 solutions. In a statement the company said the new site meet will high sustainability and eco-efficiency standards.
The construction of the new site in Zaragoza is part of BD’s $1.2 billion investment planned over four years, as part of the company’s strategy to improve manufacturing capacity and technology for pre-fillable syringes (PFS) and advanced drug delivery systems (ADDS).
Lourdes López, general director of BD in Spain and Portugal, said: “After the December 2020 announcement of BD’s intention to build a new plant in Europe, a detailed site location search process resulted in Zaragoza, Aragon being selected because of the optimal conditions offered by the region, the synergies that could be produced with BD’s Fraga facility, and the results and excellent performance of the plants that currently exist in Spain.”
BD has had sites in Spain over the last 40 years and currently has three production plants located in San Agustín de Guadalix, Fraga, and Almaraz. These facilities produce a total of 10 billion medical devices each year and employ 1,500 people. The Fraga plant is a key production site for the manufacture of COVID-19 vaccination injection devices.
Eric Borin, worldwide president of BD Pharmaceutical Systems, said: “BD’s new plant in Zaragoza will produce drug delivery devices, primarily for pharmaceutical companies that supply the European market with drugs in pre-fillable syringes such as vaccines and other biologic drugs.
“This new plant will also add needed capacity to support major vaccination campaigns, such as the one currently taking place in response to the COVID-19 pandemic.”
Kat Jenkins
Related Content
Ardena announces €20m expansion following first GMP approval
Ardena has announced that it has received Good Manufacturing Practice (GMP) approval from the Dutch …
Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn
Lonza has announced that it has signed an agreement to acquire the Genentech large-scale biologics …
AbbVie invests $223m in Singapore manufacturing site
AbbVie has announced that it has invested $223m in an expansion to its Singapore manufacturing …
